OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
The expected growth of the global bio/pharmaceutical market is pushing for the continued evolution of the CDMO arena.
Contract manufacturing services for GMP-grade RNA are in demand.
Biologic drugs used in clinical trials need technologies to meet the unique requirements of each study.
June 08, 2021
VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.
AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.
June 01, 2021
The increased number of regulatory filings for cell and gene therapies requires reevaluation of bioassay methods because of their complexity.
Outsourcing method development offers multiple benefits to companies, including access to experience and expertise, streamlined costs, and development time efficiencies.
May 16, 2021
As the RNA therapeutic market grows, contract manufacturing services for GMP-grade RNA are in demand and expected to continue on an upward trajectory.
Assessing biosafety using NGS-based tests requires a continuum of skills in molecular biology, biocomputing, virology, and quality systems.
The COVID-19 pandemic has triggered additional considerations to supplier oversight of contract manufacturing facilities.
May 15, 2021
Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.
May 02, 2021
Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.